



Quality of Science, Speed of Execution,  
Passion for Improving the lives of Patients

CORPORATE FACT SHEET | MAY 2013

## SYNTA OVERVIEW

Synta Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products for extending and enhancing the lives of patients with severe medical conditions, including cancer and chronic inflammatory disease. Synta has a unique chemical compound library, an integrated discovery engine, and a pipeline of small molecule drug candidates with novel chemical structures and distinct mechanisms of action. All drug candidates were invented internally by Synta scientists using our compound library and discovery capabilities.

## COMPANY HIGHLIGHTS

**Strong pipeline of novel internally-developed candidates in cancer and inflammatory disease** including: **ganetespib**, a second-generation, small molecule Hsp90 inhibitor; **elesclomol**, a first-in-class inhibitor of mitochondrial energy production; **STA-9584**, a dual-acting vascular disrupting agent; an oral/topical **IL-12/IL-23** inhibitor program for autoimmune and inflammatory diseases; and a **CRACM** ion channel inhibitor program for chronic inflammatory diseases and transplant rejection. All programs are 100% owned by Synta.

**Unique drug discovery engine** that has generated all Synta compounds to date and continues to generate promising, novel, small-molecule drug candidates. Platform based on unique chemical compound library; high throughput screening and in vivo modeling capabilities; medicinal, computational, analytic, process-development chemistry expertise; in vitro and in vivo toxicology and DMPK experience.

**Strong financial position** with \$90.4 million in cash as of March 31, 2013. The Company expects cash resources will be sufficient to fund operations into the second half of 2014.

**Strong intellectual property position** with portfolio of over 800 issued or pending patents. All Synta compounds currently in clinical trials represent novel chemical structures protected by issued or allowed composition of matter patents and related structure, mechanism, formulation, manufacturing, and administration patents.

This document may contain forward-looking statements about Synta Pharmaceuticals Corp. including statements relating to the timing and progress of our clinical and preclinical programs, and cash resources to be sufficient to fund operations into the second half of 2014. These forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those risks and uncertainties described under "Risk Factors" in our Form 10-K for the year ended December 31, 2012 as filed with the Securities and Exchange Commission. Synta undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

## AT-A-GLANCE

As of May 10, 2013  
NASDAQ: SNTA  
Recent price: \$7.83  
52-week range: \$3.71 - \$11.88  
Shares outstanding: 69.1 million  
Market cap: \$541.1 million

## SENIOR MANAGEMENT

**Safi Bahcall, Ph.D.**  
President, Chief Executive Officer

**Amar Singh, M.B.A.**  
SVP, Chief Business Officer

**Vojo Vukovic, M.D., Ph.D.**  
SVP, Chief Medical Officer

**Suresh Babu, Ph.D.**  
VP, Drug Product Development

**Keith Ehrlich, C.P.A.**  
VP, Chief Financial Officer

**Iman El-Hariry, M.D., Ph.D.**  
VP, Clinical Research

**Arthur McMahon**  
VP, Human Resources

**Christine Redmond, M.P.H.**  
VP, Operations & Program Management

**Wendy Rieder, Esq.**  
VP, General Counsel

**Dvorit Samid, Ph.D.**  
VP, Medical Affairs

**Andrew Sonderfan, Ph.D., DABT**  
VP, Drug Disposition & Preclinical Safety

**Thomas Wilson**  
VP, Quality Assurance

**Ilker Yalcin, Ph.D., M.B.A.**  
VP, Biostatistics & Data Management

## IR CONTACT

**George Farmer, Ph.D.**  
VP, Corporate Development  
(781) 541-7213  
ir@syntapharma.com

Synta Pharmaceuticals Corp.  
45 Hartwell Avenue  
Lexington, MA 02421  
Tel: (781) 274-8200  
Fax: (781) 274-8228

ONCOLOGY	LEAD OPT	PRE- CLINICAL	PHASE I	PHASE II	PHASE III
<b>Ganetespib (Hsp90i)</b>					
NSCLC - 2 <sup>nd</sup> line docetaxel+/- ganetespib	GALAXY-2 (N=500)				
	GALAXY-1 (N=300)				
Breast (HER2-negative)					
ALK+ NSCLC					
ISTs (NSCLC, breast, colorectal, heme, other)					
Additional combinations					
<b>Elesclomol (mitochondria)</b>					
Ovarian					
AML					
<b>STA-9584 (VDA)</b>					
<b>INFLAMMATION</b>					
CRAC inhibitors					
Hsp90i - inflamm					
IL-12/23 inhibitors					

#### ONCOLOGY:

- Ganetespib:** Second-generation, small molecule inhibitor of heat shock protein 90 (Hsp90), a chaperone regulating numerous proteins that drive tumor growth and proliferation. Over 700 patients treated to date across 20 trials. Observed single-agent clinical activity in multiple tumor types including ALK+ NSCLC, HER2+ and triple negative breast cancer. Interim results from ongoing randomized 800-patient GALAXY program evaluating ganetespib and docetaxel as second-line NSCLC therapy showed overall survival, progression-free survival, and response rate improvements in ganetespib arm vs. control arm. Based on current projections, the Company expects final progression-free survival and updated overall survival results from the 300-patient GALAXY-1 Phase 2b/3 trial in the second half in 2013, and expects to conduct interim and final analyses for the overall survival primary endpoint of the 500-patient GALAXY-2 Phase 3 trial in 2014.
- Elesclomol:** Triggers apoptosis through disrupting mitochondrial energy metabolism of cancer cells. Established that LDH and certain other markers of cancer cell metabolism are predictive of elesclomol anti-cancer activity. In three randomized trials, involving over 800 patients, clinical activity was shown in the marker positive patient population. A GOG-sponsored Phase 2 trial in ovarian cancer in combination with paclitaxel and a Phase 1 trial in AML are ongoing.
- STA-9584:** A dual-acting vascular disrupting agent that has exhibited anti-tumor activity in preclinical models, including activity against large, established tumors.

#### INFLAMMATION:

- Calcium release activated calcium modulator (CRACM) ion channel inhibitors:** Compounds that modulate the calcium signaling pathway in immune cells that drives inflammatory responses, including secretion of TNF $\alpha$  and IL-2. In preclinical models, Synta CRACM inhibitors have shown *in vivo* inhibition of TNF $\alpha$  and IL-2 and activity in immune disease models including rheumatoid arthritis, psoriasis, and inflammatory bowel diseases.
- IL 12/ 23 Inhibitors:** Novel, small molecule drug candidates that inhibit the production of the cytokines interleukin-12 (IL-12), and interleukin-23 (IL-23) in preclinical models, down-regulating inflammation pathways that drive certain autoimmune and inflammatory diseases.

